Pliva wraps $32 million VoSpire divestment

By Jennifer Chiou

New York, Nov. 8 - Pliva d.d. announced the completion of the divestment of subsidiary Odyssey Pharmaceuticals Inc.'s VoSpire to DAVA Pharmaceuticals Inc.

The company said it received $32 million upon closing as well as the right to additional potential payments of up to $35.5 million for the achievement of milestones.

Pliva, based in Zagreb, Croatia, is a pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.